<?xml version='1.0' encoding='utf-8'?>
<document id="23436267"><sentence text="Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations."><entity charOffset="21-33" id="DDI-PubMed.23436267.s1.e0" text="ketoconazole" /><entity charOffset="77-85" id="DDI-PubMed.23436267.s1.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.23436267.s1.e0" e2="DDI-PubMed.23436267.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23436267.s1.e0" e2="DDI-PubMed.23436267.s1.e1" /></sentence><sentence text="BMS-690514, a selective inhibitor of the ErbB and vascular endothelial growth factor receptors, has shown antitumor activity in early clinical development" /><sentence text=" The compound is metabolized by multiple enzymes, with CYP3A4 responsible for the largest fraction (34%) of metabolism" /><sentence text=" It is also a substrate of P-glycoprotein (P-gp) in vitro" /><sentence text=" To assess the effect of ketoconazole on BMS-690514 pharmacokinetics, 17 healthy volunteers received 200 mg BMS-690514 alone followed by 100 mg BMS-690514 with ketoconazole (400 mg once daily for 4 days)"><entity charOffset="25-37" id="DDI-PubMed.23436267.s5.e0" text="ketoconazole" /><entity charOffset="160-172" id="DDI-PubMed.23436267.s5.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.23436267.s5.e0" e2="DDI-PubMed.23436267.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23436267.s5.e0" e2="DDI-PubMed.23436267.s5.e1" /></sentence><sentence text=" The AUC(∞)  of 100 mg BMS-690514 concomitantly administered with ketoconazole was similar to that of 200 mg BMS-690514 alone"><entity charOffset="66-78" id="DDI-PubMed.23436267.s6.e0" text="ketoconazole" /></sentence><sentence text=" The dose-normalized C(max)  and AUC(∞)  of BMS-690514 from the 100-mg BMS-690514/400-mg ketoconazole treatment increased by 55% and 127%, respectively, relative to those from 200 mg BMS-690514 alone"><entity charOffset="89-101" id="DDI-PubMed.23436267.s7.e0" text="ketoconazole" /></sentence><sentence text=" Prediction of the drug-drug interaction (DDI) using a population-based simulator (Simcyp) indicated that, in addition to CYP3A4 inhibition, the inhibition of P-gp by ketoconazole in the intestine, liver, and kidneys must be invoked to fully account for the DDI observed"><entity charOffset="167-179" id="DDI-PubMed.23436267.s8.e0" text="ketoconazole" /></sentence><sentence text=" This finding suggests that the inhibition of P-gp by ketoconazole, along with its effect on CYP3A4, needs to be considered when designing a DDI study of ketoconazole with a victim drug that is a dual substrate"><entity charOffset="54-66" id="DDI-PubMed.23436267.s9.e0" text="ketoconazole" /><entity charOffset="154-166" id="DDI-PubMed.23436267.s9.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.23436267.s9.e0" e2="DDI-PubMed.23436267.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23436267.s9.e0" e2="DDI-PubMed.23436267.s9.e1" /></sentence><sentence text="" /></document>